Home › Compare › PHASQ vs GBDC

PHASQ vs GBDC: Dividend Comparison 2026

PHASQ yields 200000000.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHASQ wins by $4.875657285131069e+59M in total portfolio value
10 years
PHASQ
PHASQ
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full PHASQ calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — PHASQ vs GBDC

📍 PHASQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASQGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHASQ + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PHASQ pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHASQ
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, PHASQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHASQ + GBDC for your $10,000?

PHASQ: 50%GBDC: 50%
100% GBDC50/50100% PHASQ
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

PHASQ
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
-42.8
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHASQ buys
0
GBDC buys
0
No recent congressional trades found for PHASQ or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASQGBDC
Forward yield200000000.00% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$4.875657285131069e+59M$20.85M ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$16,450,733.83
Total dividends collected$4.875656971401711e+59M$20.43M ✓
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: PHASQ vs GBDC ($10,000, DRIP)

YearPHASQ PortfolioPHASQ Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$12,492$1,791.70+$20000.00M → PHASQ
2$37,383,218,970,104,910$37,383,197,570,093,464.00$16,527$3,160.58+$37383218970.09M → PHASQ
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$23,588$5,904.90+$65303942472059152.00M → PHASQ
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$37,141$11,901.65+$1.0661500906030689e+23M → PHASQ
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$66,205$26,463.38+$1.6267227396708296e+29M → PHASQ
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$137,452$66,612.65+$2.319663403067553e+35M → PHASQ
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$342,372$195,298.53+$3.091381823051466e+41M → PHASQ
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$1,053,292$686,954.33+$3.850317772522584e+47M → PHASQ
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$4,111,439$2,984,416.95+$4.481844117993459e+53M → PHASQ
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$20,849,974$16,450,733.83+$4.875657285131069e+59M → PHASQ

PHASQ vs GBDC: Complete Analysis 2026

PHASQ — Stock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHASQ Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this PHASQ vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHASQ vs SCHDPHASQ vs JEPIPHASQ vs OPHASQ vs KOPHASQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.